Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $28.70 billion
- Book Value:
- Revenue TTM:
- $23.52 billion
- Operating Margin TTM:
- Gross Profit TTM:
- $15.53 billion
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Coloplast A had its IPO on under the ticker symbol CLPBY.
The company operates in the Healthcare sector and Medical Instruments & Supplies industry. Coloplast A has a staff strength of 14,500 employees.
Shares of Coloplast A opened at $13.05 at the start of the last trading session i.e. 2023-03-31.
The stocks traded within a range of $13.05 - $13.2, and closed at $13.14.
This is a +2.99% increase from the previous day's closing price.
A total volume of 50,245 shares were traded at the close of the day’s session.
In the last one week, shares of Coloplast A have increased by +8.87%.
Coloplast A's Key Ratios
Coloplast A has a market cap of $28.70 billion, indicating a price to book ratio of 22.4646 and a price to sales ratio of 1.1347.
In the last 12-months Coloplast A’s revenue was $23.52 billion with a gross profit of $15.53 billion and an EBITDA of $7.76 billion. The EBITDA ratio measures Coloplast A's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Coloplast A’s operating margin was 29.97% while its return on assets stood at 17.14% with a return of equity of 75.07%.
In Q4, Coloplast A’s quarterly earnings growth was a negative -6.3% while revenue growth was a positive 18.1%.
Coloplast A’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $0.31 per share while it has a forward price to earnings multiple of 33.3333 and a PEG multiple of 3.3942. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Coloplast A’s profitability.
Coloplast A stock is trading at a EV to sales ratio of 1.2771 and a EV to EBITDA ratio of 3.9889. Its price to sales ratio in the trailing 12-months stood at 1.1347.
Coloplast A stock pays annual dividends of $20 per share, indicating a yield of 2.21% and a payout ratio of 86.53%.
Balance sheet and cash flow metrics
- Total Assets
- $35.22 billion
- Total Liabilities
- $10.48 billion
- Operating Cash Flow
- Capital Expenditure
- $275 million
- Dividend Payout Ratio
Coloplast A ended 2023 with $35.22 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $35.22 billion while shareholder equity stood at $5.91 billion.
Coloplast A ended 2023 with $0 in deferred long-term liabilities, $10.48 billion in other current liabilities, 216000000.00 in common stock, $6.45 billion in retained earnings and $0 in goodwill. Its cash balance stood at $671.00 million and cash and short-term investments were $881.00 million. The company’s total short-term debt was $5,168,000,000 while long-term debt stood at $16.36 billion.
Coloplast A’s total current assets stands at $9.28 billion while long-term investments were $0 and short-term investments were $210.00 million. Its net receivables were $3.95 billion compared to accounts payable of $964.00 million and inventory worth $3.40 billion.
In 2023, Coloplast A's operating cash flow was $0 while its capital expenditure stood at $275 million.
Comparatively, Coloplast A paid $0.87 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Coloplast A stock is currently trading at $13.14 per share. It touched a 52-week high of $15.564 and a 52-week low of $15.564. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $11.9 and 200-day moving average was $11.43 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 1.6% are held by institutions.
Frequently Asked Questions About Coloplast A
Similar Industry Stocks (Medical Instruments & Supplies)
Coloplast A/S develops and sells intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Interventional Urology, Voice and Respiratory Care, and Wound & Skin Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, it offers voice and respiratory products, including medical devices for neck stoma under the Provox brand; and products for tracheostoma under the TRACOE brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.